ANVS

Annovis Bio, Inc.

7.28 USD
-0.01 (-0.14%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Annovis Bio, Inc. stock is down -59.58% since 30 days ago. The next earnings date is Aug 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 20 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 10 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
15 May 19:37 19 Jul, 2024 2.50 PUT 1615 3682
15 May 19:37 19 Jul, 2024 2.50 PUT 1403 3682
16 May 15:51 19 Jul, 2024 2.50 PUT 1009 10295
16 May 17:53 21 Jun, 2024 7.50 PUT 150 641
16 May 19:27 19 Jul, 2024 5.00 PUT 291 3979
17 May 19:02 17 May, 2024 10.00 PUT 201 1911
17 May 19:05 17 May, 2024 10.00 PUT 200 1911
21 May 16:38 19 Jul, 2024 5.00 PUT 158 4502
21 May 16:38 19 Jul, 2024 5.00 PUT 430 4502
21 May 16:38 19 Jul, 2024 5.00 PUT 182 4502

About Annovis Bio, Inc.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for Alzheimer's disease.

  • HC Wainwright & Co.
    Mon May 13, 07:48
    buy
    confirm
  • Canaccord Genuity
    Tue Apr 30, 08:01
    buy
    confirm
  • HC Wainwright & Co.
    Tue Apr 30, 06:23
    buy
    confirm